Sustained Impact of Task-shifting HCV Treatment to Nonspecialist Providers: 5-Year Follow Up of the ASCEND Investigation
DAA is an effective treatment for HCV and can safely be prescribed by multiple provider types, with favorable long-term outcomes.
Authors
- Sarah Kattakuzhy (ORCID: https://orcid.org/0000-0002-3433-3597)
- Elana Rosenthal (ORCID: https://orcid.org/0000-0001-7234-4871)
- Sarah Mollenkopf (ORCID: https://orcid.org/0000-0001-9214-2492)
- Nivya George
- Shyam Kottilil (ORCID: https://orcid.org/0000-0001-7471-0812)
- Henry Masur (ORCID: https://orcid.org/0000-0002-3688-021X)
- Rachel Silk
- G. Teferi
Institutions
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Consumer Healthcare Products Association (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1093/ofid/ofaf174
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00